Global Melphalan Injection Market Size, Share, Analysis, Applications, Growth Insight, and Future Forecast - 2028

The global melphalan injection market is anticipated to grow at a considerable CAGR 4% during the forecast period (2022-2028). Melphalan is widely used as an intravenous injection and high doses of Melphalan are used intravenously as high doses show promising results. As intravenous use is the highest dose injection powder increase and 50 mg vial lyophilized powder used is a single-dose vial. Therefore, injection powder, lyophilized, to obtain a solution will lead the market during the forecast year.
Melphalan is used in various preparations and promoted by many brand names. The number of patients diagnosed with multiple myeloma is increasing day by day. The number of patients with multiple myeloma has increased rapidly in the US over the years. Considering the year 2020 there are more than 32000 recorded cases of multiple myeloma in the US and it is expected that more than 12000 mortalities will occur due to it. Multiple myeloma is the most common blood cancer in the US and the overall mortality rate due to multiple myeloma has increased over the years. Melphalan is widely used in the treatment of multiple myeloma which helps to prolong the life of patients this feature will improve Melphalan acceptance for the treatment of multiple myeloma in the forecasted period.
Additionally, it is an alkylating agent that attaches chemical molecules to DNA, Melphalan reduces myeloma cells rapidly breaking down into cells and helps regulate cell duplication. In myeloma, high doses of Melphalan are used and this high ingredient is effective in reducing myeloma cells. Melphalan and Autologous stem cell transplantation had better results than traditional chemotherapy. Patients 65 years of age or younger have shown promising treatment results thus increasing drug acceptance in the coming years. The overall survival rate for patients with multiple myeloma is 74.0% and when cancer has spread to other areas the survival rate drops to 51.0%. As a result of advances in chemotherapy, the overall survival rate has increased in the US over the years. The government's move to reduce the number of cancer deaths and improve cancer treatments is boosting the Melphalan injection market growth over the forecast period.

In February 2021, the Food and Drug Administration granted immediate approval for melphalan flufenamide in combination with dexamethasone in elderly patients with multiple recurrent or severe myeloma who received at least four treatment lines and a disease not associated with at least one proteasome inhibitor, an immunomodulatory agent, as well as a single CD-38 targeted monoclonal antibody. Such drug approvals are further anticipated to drive the market growth.

(Get 15% Discount on Buying this Report)

Get Sample Copy of Global Melphalan Injection Market at:
https://orionmarketreports.com/request-sample/?id=96437&submit=Request+Sample%0D%0A

Market Coverage
• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

• Segment Covered-
o By Type
o By Application

• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World

• Competitive Landscape- Athenex, Dr. Reddy's, Fresenius Kabi, Mylan N.V., Spectrum Pharmaceuticals, among others.

Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

A full report of Global Melphalan Injection Market is available at:
https://orionmarketreports.com/global-melphalan-injection-market/96437/

Global Melphalan Injection Market Report by Segment

By Type
• 50mg/vial
• 10mg/vial

By Application
• Hospital
• Clinics
• Recovery Center

Global Melphalan Injection Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa

Company name: Orion Market Reports
Contact person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404

About us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.